visilizumab

Newer monoclonal antibodies with the same mechanism of action include otelixizumab, teplizumab and visilizumab.

Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells.

Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody.

PDL BioPharma, Inc. canceled production of visilizumab following its Phase II/III clinical trials, citing its inefficacy and poor safety profile compared to other drugs on the market as the major reasons.